Feedback PLC AIM RULE 26

The information contained within this section of the website is for the purposes of AIM Rule 26.


Feedback plc was founded in 1958 and has been listed on the AIM market of the London Stock Exchange since 2007.

Feedback plc (AIM: FDBK) is a specialist medical imaging technology company providing innovative software and systems through our fully owned trading subsidiary, Feedback Medical Limited. Their products advance the work of radiologists, clinicians and medical researchers by improving workflows and giving unique insights into diseases, particularly cancer. Feedback Medical work with customers globally from our headquarters in London, UK. Their proprietary technologies are TexRAD, the quantitative texture analysis tool and Cadran, a picture archiving communication system (PACS).

Bleepa® is a secure instant messaging system which facilitates the sharing of clinical-grade medical images between personal devices, such as smartphones and tablets. Developed by Feedback Medical, Bleepa’s unique technology allows the discussion, review and decision-making surrounding clinical-grade images to happen in real time, from any location. This powerful technology has the potential to revolutionise the speed and quality of patient management, changing the lives and practices of doctors all across the world.

TexRAD is a patent-protected software tool which extracts and quantifies texture features in radiological images, assisting research into all tumour types. In the exciting new field of radiomics, TexRAD uncovers biomarkers in medical images which are invisible to the naked eye. TexRAD has featured in over 100 academic publications, won numerous awards and is currently used in over 50 prestigious institutions worldwide. Feedback Medical have recently launched TexRAD Lung, a software tool for the analysis of lung cancer, which is CE marked for clinical use in the EU.

The Cadran image platform provides hospitals and research institutes with a comprehensive picture archiving communication system (PACS) for medical images. It equips users with a flexible, convenient and secure platform for image handling from all imaging modalities, such as CT and PET scanners. Cadran originates from developments by professionals working in real-life medical environments and has been advanced in close cooperation with researchers, radiologists and healthcare IT specialists to ensure user confidence and relevance in today’s medical world. Cadran Viewer is a Medical Device which is CE marked for clinical use in the EU.


View information on the company directors here.

Corporate Governance

View information on corporate governance here.

UK Takeover Code Applicability

The Company is a public company incorporated in the UK and has its place of central management and control in the UK. Accordingly, the Takeover Code applies to the Company and, as a result, Shareholders are entitled to the benefits of the takeover offer protections provided under the Takeover Code.

Country of Incorporation and Operations

Country of incorporation: England and Wales
Company registration number: 598696
Main country of operation: United Kingdom

Company Documents

AIM Admission document

Articles of Association


AGM Notice – September 2022

Circular and GM Notice – November 2021

Circular and GM Notice – June 2020

Circular and GM Notice – August 2019

Circular and GM Notice – June 2018

Circular and Notice of GM – October 2018

Annual Reports and Accounts

View the Annual Reports and Accounts here for the last three years.

Details of Restrictions on the Transfer of Securities

There are no restrictions on the transfer of ordinary shares.

Details of any other Exchanges

The securities of the Company are traded on the AIM market operated by the London Stock Exchange plc. Its shares have not been admitted, nor have any applications been made, for any of its shares to be admitted or traded on any other exchanges or trading platform.

Securities Information

AIM securities in issue: As at 25 July 2022 there were 2,666,931,677 ordinary shares in issue. The Company does not hold any shares in treasury.

As at 25 July 2022, the percentage of shares not held in public hands and insofar as the Company is aware (as defined by AIM rule 26) was 68.01%.

View the identity and shareholdings of the Company’s significant shareholders here.

Advisor Information

View all Company Advisor Information here.

Registered Address

Regulatory News

This information was last updated on 1 November 2022.